Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Poll

May 07, 2013

Alzheimer’s Research

Baxter International’s drug candidate Gammagard is the latest Alzheimer’s therapeutic to fail in meeting its clinical endpoints. A number of other potential therapies have suffered similar fates. With these failures in mind, how can Alzheimer’s sufferers remain optimistic that relief is in sight?

Do you foresee a major breakthrough in the treatment of Alzheimer’s disease within the next 10 years?

  {{ choice.Percent }}%